Form 8-K - Current report:
SEC Accession No. 0000950170-25-056821
Filing Date
2025-04-22
Accepted
2025-04-22 16:45:23
Documents
21
Period of Report
2025-04-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K neog-20250422.htm   iXBRL 8-K 39478
2 EX-99.1 neog-ex99_1.htm EX-99.1 10133
3 GRAPHIC neog-ex99_1s1.jpg GRAPHIC 348449
4 GRAPHIC neog-ex99_1s2.jpg GRAPHIC 511615
5 GRAPHIC neog-ex99_1s3.jpg GRAPHIC 405367
6 GRAPHIC neog-ex99_1s4.jpg GRAPHIC 584824
7 GRAPHIC neog-ex99_1s5.jpg GRAPHIC 189804
8 GRAPHIC neog-ex99_1s6.jpg GRAPHIC 537743
9 GRAPHIC neog-ex99_1s7.jpg GRAPHIC 354369
10 GRAPHIC neog-ex99_1s8.jpg GRAPHIC 397148
11 GRAPHIC neog-ex99_1s9.jpg GRAPHIC 128603
  Complete submission text file 0000950170-25-056821.txt   4929019

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT neog-20250422.xsd EX-101.SCH 25023
23 EXTRACTED XBRL INSTANCE DOCUMENT neog-20250422_htm.xml XML 4730
Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 8-K | Act: 34 | File No.: 000-17988 | Film No.: 25858249
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)